RhumbLine Advisers
CINC

RhumbLine Advisers’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

RhumbLine Advisers’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,427
Closed -$399K – 2985
2022
Q4 		$399K Buy
32,427
+4,811
+17% +$115K ﹤0.01% 2577
2022
Q3 		$906K Buy
27,616
+8,511
+45% +$241K ﹤0.01% 2183
2022
Q2 		$360K Buy
+19,105
New +$366K ﹤0.01% 2659

RhumbLine Advisers's CINC Position: Q1 2023 in Review

RhumbLine Advisers sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 32,427 shares — an estimated $399K sold.

RhumbLine Advisers first reported a position in CINC in Q2 2022 and held it in 3 quarters. The position peaked at $906K in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

  • RhumbLine Advisers reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 32,427 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $399K.
  • RhumbLine Advisers first reported a position in CinCor Pharma, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • RhumbLine Advisers's CinCor Pharma, Inc. Common Stock position peaked at $906K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on RhumbLine Advisers's 13F filing for Q1 2023, filed 11 May 2023.